START STRONG and STAY STRONG with EYLEA®

Flexible, proactive dosing across indications1

Dosing table for nAMD label
  • EYLEA extended dosing can reduce treatment burden1
  • There is no requirement for monitoring between injections1
Dosing table for DME, RVO and mCNV

a The recommended dose for EYLEA is 2 mg aflibercept, equivalent to 50 microliters. EYLEA treatment is initiated with one injection per month for three consecutive doses. The treatment interval is then extended to 8 weeks. Based on the physician’s judgment of visual and/or anatomic outcomes, the treatment interval may be maintained at 8 weeks or further extended using a treat-and-extend dosing regimen, where injection intervals are increased in 2- or 4-weekly increments to maintain stable visual and/ or anatomic outcomes. The schedule of monitoring visits may be more frequent than the injection visits. Treatment intervals greater than 16 weeks between injections have not been studied.
Beyond 52 weeks the treatment interval may be extended, such as with a treat-and-extend dosing regimen, where the treatment intervals are gradually increased to maintain stable visual and/or anatomic outcomes; however, there are insufficient data to conclude the length of time of these intervals. For further dosing information please refer to the EYLEA Summary of Product Characteristics (SmPC).
b Recurrence of mCNV should be treated as a new manifestation of the disease.

DME, diabetic macular edema; mCNV, myopic choroidal neovascularization; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion; T&E, treat-and-extend.

Reference

  1. EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; July 2018.